The National Institutes of Health is placing its next big bet on cancer vaccines. In an interview marking his first year as director of the National Cancer Institute, Anthony Letai revealed that the therapeutic cancer vaccine public-private partnership spearheaded by NCI and led by the Foundation for the NIH (FNIH) is "going very well": a white paper is out, sketching the skeleton of two to three upcoming clinical trials, and FNIH is now collecting corporate funding commitments toward a $200 million target.
In the interview published October 7 by The Cancer Letter, Letai said: "I think it's going very well. We're at this stage now — there's a white paper that's out, and it, I think, does a good job laying out the skeleton of how we want to progress, which is two to three clinical trials investigating — it prioritizes some of the different tumors we'd want to investigate." When the plan first surfaced in March, Letai set the tone by asking his team: "How aggressive can we be?" His June report to the National Cancer Advisory Board added the operating details: multiple vaccine platforms in parallel, each trial with clear go/no-go criteria.
"This is going to be a public-private partnership. This is being led by the FNIH, the Foundation for NIH," Letai said. "And right now, FNIH is busy sort of raising money for the private part of that." Asked whether the money is coming in, he answered: "Yes. Well, they're in the business right now of collecting the commitments." According to Science magazine, NCI is partnering with companies to raise $200 million for clinical trials testing personalized cancer vaccines based on messenger RNA (mRNA). The FNIH is a congressionally established nonprofit that manages NIH's public-private partnerships.
The white paper sets the technical course: start with two to three clinical trials, advancing the most promising emerging cancer vaccine technologies to the clinic while spelling out which are not ready. Letai stressed that NCI will not compete head-on with industry: "Our job here is not to directly compete with commercial entities, but to investigate techniques, approaches, and also disease contexts that are not being fully studied in the commercial world." Every trial will run multiple platforms in parallel with staged reviews — advance what works, kill what doesn't.
The most notable part is the targeting strategy: NCI wants the hard problems companies won't touch. "We specifically want to go after niches, or contexts, that are not being explored by commercial entities," Letai said. "And I want to mention — that includes some pediatric tumors." Pediatric cancers affect few patients and offer small markets, so big pharma invests little — exactly where public money should fill the gap. That positioning has earned the plan goodwill among researchers: unlike some of NCI's more controversial projects, almost no scientist has publicly objected to the vaccine initiative.
NIH is betting big because the science is ripening. At least 50 cancer vaccine clinical trials are active across the U.S., Europe, and Asia, targeting more than 20 types of cancer. Furthest along is the personalized mRNA vaccine from Moderna and Merck: the Phase 3 INTerpath-001 trial in high-risk melanoma met its main goals, with full data expected later in October at the European oncology conference ESMO. Personalized melanoma vaccines could reach patients as early as 2028. In late September, the New York Post profiled a fibrolamellar carcinoma patient who went into remission on an off-the-shelf vaccine after preparing to die. The catch: personalized vaccines still cost over $100,000 per dose to manufacture, and bringing that down is the key hurdle to real-world use.
The plan has one surprising backer: Health Secretary Robert F. Kennedy Jr. According to Science, Kennedy himself pushed for the mRNA cancer vaccine initiative — even as he has repeatedly questioned the safety of mRNA COVID vaccines and cut mRNA funding for infectious diseases. Letai relayed Kennedy's logic: treating people "who are sick, have cancer, and have, in most cases, a fairly dire life expectancy" is "a very distinct context" from vaccinating 300 million healthy people, "and the risk-benefit ratio has to be considered very differently." Against a backdrop of funding turmoil across NIH, NCI's budget actually grew this year — appropriations added over $120 million — stocking ammunition for the big bet.
Per Letai's timeline, the next step is for FNIH to finish collecting corporate commitments, followed by a formal open competition for trial sites and the individual trials, with details to come in the solicitation. If the $200 million lands, two to three clinical trials will launch over the next three years. For patients, it means the technology proven in the COVID era — training the immune system to recognize and kill cancer cells — may for the first time be aimed at cancer at the scale of a national program.